ValiRx Updates Shareholding in Ambrose Healthcare Following AM-Pharma Acquisition
ValiRx confirmed its 5.55% equity stake in Ambrose Healthcare following the latter's acquisition of AM-Pharma for up to €161 million.
Stocks · News reference
Susquehanna Maintains Neutral on Valaris, Raises Price Target to $86
Susquehanna analyst Charles Minervino maintains Valaris (NYSE:VAL) with a Neutral and raises the price target from $80 to $86.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Valaris Deploys CleanSight® Technology on DS-9 Drillship
Valaris has expanded the deployment of DrillDocs' CleanSight® technology to its DS-9 ultra-deepwater drillship in Angola, following successful validations in Guyana.
Transocean Advances $5.8B Valaris Deal With Brazil Antitrust Nod
Transocean has received unconditional antitrust approval from Brazil's CADE for its $5.8 billion all-stock acquisition of Valaris, following earlier U.S. Department of Justice clearance. The deal, expected to close in Q4 2026, will create a 73-rig diversified fleet with over $200 million in cost synergies and a $10 billion backlog, positioning the combined company as an offshore drilling industry leader.
Valaris' Latest Contract Awards Add $220M to Contract Backlog
Valaris Ltd. (VAL) announced multiple contract awards and extensions totaling approximately $220 million added to its backlog. Key wins include a 300-day offshore drilling contract in Australia worth $50 million, a North Sea plug and abandonment contract valued at $41.5 million, and contract extensions with INEOS, Seatrium, and Eni. These awards are expected to enhance fleet utilization and provide future revenue visibility.